Daewoong pharmaceutical Co.,Ltd (069620.KS)
KRW 125500.0
(-2.64%)
KRW 125500.0
(-2.64%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 241.54 Billion KRW | 15.72% |
| 2022 | 208.73 Billion KRW | 19.24% |
| 2021 | 175.05 Billion KRW | 0.62% |
| 2020 | 173.97 Billion KRW | -2.05% |
| 2019 | 177.6 Billion KRW | -6.04% |
| 2018 | 189.03 Billion KRW | 1.08% |
| 2017 | 187.01 Billion KRW | 14.91% |
| 2016 | 162.74 Billion KRW | 12.62% |
| 2015 | 144.5 Billion KRW | 29.18% |
| 2014 | 111.86 Billion KRW | -2.85% |
| 2013 | 115.14 Billion KRW | 34.57% |
| 2012 | 85.56 Billion KRW | 1.0% |
| 2011 | 84.71 Billion KRW | 5.13% |
| 2010 | 80.58 Billion KRW | -3.05% |
| 2009 | 83.12 Billion KRW | 7.17% |
| 2008 | 77.56 Billion KRW | 6.84% |
| 2007 | 72.59 Billion KRW | 61.39% |
| 2006 | 44.98 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 249.05 Billion KRW | 3.11% |
| 2024 Q2 | 246.46 Billion KRW | -1.04% |
| 2023 Q4 | 241.54 Billion KRW | 3.57% |
| 2023 FY | 241.54 Billion KRW | 15.72% |
| 2023 Q2 | 227.11 Billion KRW | -0.83% |
| 2023 Q1 | 229 Billion KRW | 9.71% |
| 2023 Q3 | 233.22 Billion KRW | 2.69% |
| 2022 FY | 208.73 Billion KRW | 19.24% |
| 2022 Q3 | 210.4 Billion KRW | 5.58% |
| 2022 Q4 | 208.73 Billion KRW | -0.79% |
| 2022 Q2 | 199.27 Billion KRW | 8.24% |
| 2022 Q1 | 184.09 Billion KRW | 5.17% |
| 2021 Q2 | 181.64 Billion KRW | 0.46% |
| 2021 FY | 175.05 Billion KRW | 0.62% |
| 2021 Q1 | 180.81 Billion KRW | 3.93% |
| 2021 Q3 | 181.9 Billion KRW | 0.14% |
| 2021 Q4 | 175.05 Billion KRW | -3.77% |
| 2020 Q2 | 193.86 Billion KRW | 0.61% |
| 2020 Q1 | 192.69 Billion KRW | 8.49% |
| 2020 FY | 173.97 Billion KRW | -2.05% |
| 2020 Q3 | 180.61 Billion KRW | -6.83% |
| 2020 Q4 | 173.97 Billion KRW | -3.68% |
| 2019 Q2 | 168.9 Billion KRW | -5.7% |
| 2019 FY | 177.6 Billion KRW | -6.04% |
| 2019 Q1 | 179.12 Billion KRW | -5.24% |
| 2019 Q4 | 177.6 Billion KRW | 2.57% |
| 2019 Q3 | 173.15 Billion KRW | 2.51% |
| 2018 Q3 | 216.29 Billion KRW | 5.68% |
| 2018 Q1 | 196.4 Billion KRW | 5.02% |
| 2018 FY | 189.03 Billion KRW | 1.08% |
| 2018 Q4 | 189.03 Billion KRW | -12.6% |
| 2018 Q2 | 204.67 Billion KRW | 4.21% |
| 2017 Q4 | 187.01 Billion KRW | 8.23% |
| 2017 FY | 187.01 Billion KRW | 14.91% |
| 2017 Q3 | 172.79 Billion KRW | 1.22% |
| 2017 Q2 | 170.71 Billion KRW | 1.29% |
| 2017 Q1 | 168.53 Billion KRW | 3.56% |
| 2016 Q4 | 162.74 Billion KRW | -4.38% |
| 2016 Q1 | 133.74 Billion KRW | -7.45% |
| 2016 Q2 | 161.21 Billion KRW | 20.53% |
| 2016 FY | 162.74 Billion KRW | 12.62% |
| 2016 Q3 | 170.2 Billion KRW | 5.58% |
| 2015 FY | 144.5 Billion KRW | 29.18% |
| 2015 Q2 | 124.86 Billion KRW | 6.23% |
| 2015 Q3 | 142.78 Billion KRW | 14.35% |
| 2015 Q1 | 117.53 Billion KRW | 5.07% |
| 2015 Q4 | 144.5 Billion KRW | 1.21% |
| 2014 Q2 | 119.6 Billion KRW | 2.26% |
| 2014 Q3 | 117.01 Billion KRW | -2.17% |
| 2014 FY | 111.86 Billion KRW | -2.85% |
| 2014 Q4 | 111.86 Billion KRW | -4.4% |
| 2014 Q1 | 116.97 Billion KRW | 1.59% |
| 2013 FY | 115.14 Billion KRW | 34.57% |
| 2013 Q3 | 101.26 Billion KRW | 10.46% |
| 2013 Q2 | 91.67 Billion KRW | 6.77% |
| 2013 Q4 | 115.14 Billion KRW | 13.71% |
| 2013 Q1 | 85.86 Billion KRW | 0.35% |
| 2012 Q1 | 94.75 Billion KRW | 0.0% |
| 2012 Q4 | 85.56 Billion KRW | 0.0% |
| 2012 FY | 85.56 Billion KRW | 1.0% |
| 2011 Q1 | 71.11 Billion KRW | 0.0% |
| 2011 FY | 84.71 Billion KRW | 5.13% |
| 2011 Q3 | 84.66 Billion KRW | 2.18% |
| 2011 Q2 | 82.85 Billion KRW | 16.51% |
| 2010 Q1 | 83.12 Billion KRW | 0.93% |
| 2010 FY | 80.58 Billion KRW | -3.05% |
| 2010 Q2 | 78.42 Billion KRW | -5.65% |
| 2010 Q3 | 75.77 Billion KRW | -3.38% |
| 2009 Q2 | 79.58 Billion KRW | 0.0% |
| 2009 Q4 | 82.35 Billion KRW | 5.29% |
| 2009 Q3 | 78.21 Billion KRW | -1.72% |
| 2009 FY | 83.12 Billion KRW | 7.17% |
| 2008 Q3 | 73.87 Billion KRW | 6.31% |
| 2008 Q2 | 69.49 Billion KRW | 0.0% |
| 2008 Q4 | 85.26 Billion KRW | 15.42% |
| 2008 FY | 77.56 Billion KRW | 6.84% |
| 2007 FY | 72.59 Billion KRW | 61.39% |
| 2007 Q2 | 41.52 Billion KRW | 0.0% |
| 2007 Q4 | 61.18 Billion KRW | 22.66% |
| 2007 Q3 | 49.88 Billion KRW | 20.13% |
| 2006 FY | 44.98 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -447.075% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | -104.956% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | -164.95% |
| HANDOK Inc. | 94.46 Billion KRW | -155.699% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -1037.054% |
| Yuhan Corporation | 284.75 Billion KRW | 15.175% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | -107.667% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -1385.639% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 16.366% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -645.875% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -291.327% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -1140.153% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -697.7% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -399.605% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -447.075% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -673.174% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -586.669% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -401.879% |
| JW Holdings Corporation | 147.58 Billion KRW | -63.66% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | -185.435% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 7.607% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -127.677% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -347.943% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -794.679% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -642.956% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | -120.051% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -447.075% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | -28.044% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -127.677% |
| Yuhan Corporation | 284.75 Billion KRW | 15.175% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | -92.804% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | -289.674% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 7.041% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -127.677% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | -203.438% |
| Korea United Pharm Inc. | 49.14 Billion KRW | -391.525% |
| CKD Bio Corp. | 69.08 Billion KRW | -249.649% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | -129.873% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | -241.662% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | -346.827% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -347.943% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | -24.019% |
| Boryung Corporation | 189.8 Billion KRW | -27.259% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | -325.018% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -291.327% |
| JW Lifescience Corporation | 23.39 Billion KRW | -932.307% |